Allergy Treatment Options Physician Guide: From Antihistamines to Biologics — What Allergists and Immunologists Want Every Patient to Know in 2026
Introduction: Why Allergy Treatment in 2026 Demands a New Conversation
Allergies are no longer a seasonal nuisance to be waited out with a box of tissues. More than 50 million Americans experience allergic disease every year, and according to the CDC’s 2024 National Health Interview Survey, 31.7% of U.S. adults carry at least one diagnosed allergic condition. The economic stakes are staggering: a 2025 analysis estimates that food allergies alone cost the United States nearly $371 billion annually in medical expenses, lost productivity, and diminished quality of life.
Layered on top of this is a climate reality. The freeze-free growing season has lengthened in 87% of 198 U.S. cities studied, stretching an average of 21 days between 1970 and 2025. Longer seasons mean more pollen, more potent allergens, and more suffering.
This guide, presented by Top Doctor Magazine, maps the entire allergy treatment ladder, from over-the-counter antihistamines through the 2026 ARIA-EAACI guideline updates, immunotherapy, and five FDA-approved biologics. The goal is a single, specialist-voiced, patient-accessible resource covering the treatment framework, the allergist versus immunologist distinction, emerging therapies, health equity, and digital health integration.
Understanding the Allergy Epidemic: Scope, Burden, and the Climate Factor
The CDC’s 2024 data tells a sobering story: 25.2% of U.S. adults have seasonal allergies, 7.7% have eczema, and 6.7% have a food allergy. Food allergy prevalence has risen 50% since the 1990s, and more than 200,000 emergency room visits each year stem from food allergies alone.
The $371 billion annual cost figure encompasses direct medical care, caregiver time, lost workplace productivity, and the quiet toll on daily living. Framed this way, undertreated allergies represent a public health and economic emergency rather than a personal inconvenience.
Climate change accelerates the crisis. AAFA’s 2026 Allergy Capitals Report documents unprecedented pollen levels and explicitly labels climate change a public health emergency. The mechanism is direct: warmer temperatures boost pollen production, extend growing seasons, and elevated atmospheric carbon dioxide amplifies allergen potency.
These burdens are not distributed evenly. Food allergy prevalence is rising faster among Black and Hispanic Americans, and women, Black Americans, and children are disproportionately affected. Insurance gaps further restrict access to specialist care and immunotherapy. Understanding the full treatment spectrum, not just symptom relief, has never been more urgent.
The Allergy Treatment Ladder: A Framework for Physicians and Patients
Allergy care follows a logical step-up algorithm: OTC antihistamines, then intranasal corticosteroids, then combination intranasal therapy, then allergen immunotherapy (SCIT or SLIT), then biologics, and finally emerging therapies.
This ladder is not strictly linear. Severity, allergen type, comorbidities, and biomarkers guide where each patient begins and how quickly they advance. The most important conceptual distinction is between symptom-management therapies (antihistamines, corticosteroids, and decongestants) and disease-modifying therapies (immunotherapy and biologics) that target the underlying immune dysregulation.
Primary care physicians typically manage the lower rungs. Allergists and immunologists guide decisions at the immunotherapy and biologic levels. This framework forms the backbone of everything that follows.
Step 1: Over-the-Counter and First-Line Pharmacotherapy
Second-generation oral antihistamines (cetirizine, loratadine, fexofenadine) block histamine receptors with minimal sedation. First-generation antihistamines are generally discouraged because of drowsiness and anticholinergic effects.
Intranasal corticosteroids (fluticasone, mometasone, budesonide) remain the cornerstone for persistent allergic rhinitis. Proper technique matters: aim the spray away from the septum, and expect full benefit over days, not minutes.
Decongestants offer short-term relief, but nasal forms risk rebound congestion (rhinitis medicamentosa) and carry cardiovascular cautions. Leukotriene receptor antagonists such as montelukast help with allergic rhinitis and mild asthma but carry an FDA black box warning for neuropsychiatric events. Mast cell stabilizers (cromolyn sodium) and antihistamine eye drops address ocular symptoms.
The key message: OTC options relieve symptoms but do not change the disease course. Patients with moderate-to-severe or persistent symptoms need to climb higher on the treatment ladder.
Step 2: The 2026 ARIA-EAACI Guideline Updates — What Changed and Why It Matters
ARIA (Allergic Rhinitis and its Impact on Asthma) and EAACI (European Academy of Allergy and Clinical Immunology) jointly produce the global clinical standard for allergic rhinitis management. The most significant 2026 update: combination intranasal antihistamine plus corticosteroid sprays are now recommended as first-line therapy for moderate-to-severe allergic rhinitis (Allergy, Wiley).
The rationale is mechanistic. The combination simultaneously addresses histamine-mediated and inflammatory pathways, delivering faster onset than intranasal steroids alone. The 2026 guidelines also elevate sublingual immunotherapy (SLIT) for patients with persistent moderate-to-severe seasonal allergies.
For primary care physicians still prescribing to older monotherapy standards, this is a meaningful shift. Within the treatment ladder, combination intranasal therapy now occupies a distinct rung between monotherapy and immunotherapy.
Step 3: Allergen Immunotherapy — The Disease-Modifying Standard
Allergen immunotherapy (AIT) is the only currently available treatment that modifies the underlying allergic immune response rather than suppressing symptoms. Gradual allergen exposure induces tolerance through regulatory T-cell expansion, IgG4 blocking antibody production, and reduced mast cell and basophil reactivity.
Subcutaneous Immunotherapy (SCIT): Allergy Shots
SCIT follows a build-up phase (weekly injections over 6 to 12 months) and a maintenance phase (monthly injections for 3 to 5 years). The evidence base is robust: long-term symptom reduction, less medication use, prevention of new sensitizations, and reduced asthma development in children with allergic rhinitis.
Candidates include patients with documented IgE-mediated inhalant allergies (pollens, dust mites, pet dander, and mold), inadequate pharmacotherapy response, or a desire to avoid lifelong medication. Because systemic reactions are possible, patients require 20 to 30 minutes of post-injection observation in a clinical setting with epinephrine available.
In 2025, ACAAI, AAAAI, and AAOA jointly published guidance on documentation requirements to address insurance access barriers. SCIT is administered exclusively by trained allergists, a key reason specialist referral matters.
Sublingual Immunotherapy (SLIT): Drops and Tablets
SLIT delivers allergen extracts under the tongue daily at home, available as FDA-approved tablets (grass, ragweed, and dust mite) or off-label aqueous drops. The 2026 guidelines elevate SLIT for persistent moderate-to-severe seasonal allergies, with evidence showing that three or more years of high-dose SLIT produces sustained benefits lasting at least two additional years after stopping (HCPLive).
SLIT avoids injection risk, suits patients with needle phobia or limited clinic access, and integrates naturally with telemedicine, an increasingly important model given the allergist shortage. Limitations include the need for high adherence, non-standardized dosing for off-label drops, and allergen-specific FDA-approved tablets.
Step 4: FDA-Approved Biologics — Targeted Therapy for Severe Allergic Disease
Biologics are precision medicines targeting specific cytokines or receptors in the Type 2 inflammatory pathway (IgE, IL-4, IL-5, IL-13, and TSLP). They are reserved for severe, inadequately controlled disease despite optimized conventional therapy; they are not first-line for most patients. Biomarker-guided selection relies on blood eosinophil counts, fractional exhaled nitric oxide (FeNO), total and specific IgE, and periostin.
Omalizumab (Xolair): Anti-IgE
Omalizumab binds free IgE, reducing mast cell and basophil activation across allergic pathways. It treats moderate-to-severe allergic asthma, chronic idiopathic urticaria, and, as of February 2024, multiple food allergies. This made it the first FDA-approved treatment for multiple food allergies simultaneously, raising reaction thresholds (though not curative) and offering a safety net for complex food allergy profiles. Dosing is subcutaneous every 2 to 4 weeks based on weight and IgE level.
Mepolizumab (Nucala) and Reslizumab (Cinqair): Anti-IL-5
Both target IL-5, the cytokine driving eosinophil production and survival. They treat severe eosinophilic asthma; mepolizumab is also approved for EGPA and hypereosinophilic syndrome. The key biomarker is a blood eosinophil count of roughly 150 to 300 cells/μL. Mepolizumab is subcutaneous; reslizumab is an IV infusion. Both significantly reduce exacerbations and oral corticosteroid dependence.
Benralizumab (Fasenra): Anti-IL-5 Receptor
Benralizumab targets the IL-5 receptor alpha subunit, inducing near-complete eosinophil depletion through antibody-dependent cellular cytotoxicity. After monthly loading doses, maintenance dosing every 8 weeks supports adherence. Biomarker thresholds mirror those of the other anti-IL-5 agents.
Dupilumab (Dupixent): Anti-IL-4/IL-13
Dupilumab blocks the shared IL-4/IL-13 receptor alpha subunit, inhibiting both Type 2 cytokine pathways. It has the broadest indication profile of any biologic: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and allergic fungal rhinosinusitis (AFRS). In phase 3 trials, dupilumab achieved clinical remission in 37.2% of severe asthma patients, with many sustaining remission over two years (JACI). It is self-administered subcutaneously every 2 weeks and is especially valuable for patients with multiple Type 2 comorbidities following the atopic march.
Tezepelumab (Tezspire): Anti-TSLP
Tezepelumab targets thymic stromal lymphopoietin, an epithelial cytokine that initiates the entire Type 2 cascade, making it the most upstream biologic available. It is the only biologic approved for severe asthma regardless of eosinophil count, providing an option for low-eosinophil patients who do not qualify for anti-IL-5 agents. Approved for patients 12 and older, it reduces exacerbations across all eosinophil subgroups. Trials are now exploring tezepelumab combined with SCIT, representing the frontier of biologic-immunotherapy synergy.
Emerging and Next-Generation Therapies: What’s on the Horizon
Depemokimab: Ultra-Long-Acting Anti-IL-5
Depemokimab is engineered for an extended half-life, requiring only twice-yearly dosing. Phase III results show promising efficacy for T2-high asthma, with potential to dramatically improve adherence and ease the burden for patients in underserved or rural areas where frequent visits are a barrier.
Oral Immunotherapy (OIT) and Epicutaneous Immunotherapy (EPIT) for Food Allergy
Palforzia (peanut OIT) is FDA-approved for children ages 1 to 17; notably, 67% of adults in the GUPI trial achieved desensitization, expanding interest in adult programs. The Viaskin Peanut Patch builds tolerance in over 70% of toddlers after three years per 2025 ACAAI data, making it vital for the youngest patients. Following omalizumab’s 2024 approval, multi-allergen OIT is gaining momentum, with omalizumab pre-treatment potentially enabling safer, faster desensitization. Patients should understand the difference between desensitization (protection while on therapy) and sustained unresponsiveness (lasting tolerance).
Intralymphatic Immunotherapy (ILIT) and mRNA Vaccine Approaches
ILIT delivers allergen directly into lymph nodes under ultrasound guidance, requiring as few as three injections over three months, with early studies suggesting faster desensitization. It remains investigational in the U.S. but is more advanced in Europe. mRNA vaccine technology is being explored to reprogram immune tolerance, potentially offering a curative approach for hay fever or cat allergy. Sublingual epinephrine (Anaphylm) is in development as an alternative to injectable epinephrine, with FDA review expected in 2026. These therapies are not yet standard of care but signal the field’s direction.
Allergist vs. Immunologist: Understanding the Specialist Distinction
An allergist (formally allergist/immunologist) holds dual board certification in allergy and immunology, typically after internal medicine or pediatrics plus a two-year fellowship. Their focus is IgE-mediated disease: rhinitis, asthma, food allergy, anaphylaxis, urticaria, contact dermatitis, allergen testing, and immunotherapy.
A clinical immunologist may be the same dual-trained specialist or a physician focused primarily on immune deficiency, autoimmune disease, and non-IgE immune dysregulation.
Patients should see an allergist for persistent or severe allergic rhinitis, suspected food allergy, recurrent anaphylaxis, difficult-to-control asthma, chronic urticaria, or consideration of immunotherapy or biologics. An immunologist’s expertise is primary for primary immunodeficiency diseases (CVID and SCID), recurrent infections, and autoimmune dysregulation. Complex patients may benefit from joint management.
When requesting a referral, patients should bring a symptom diary, prior test results, and a medication list. With a growing allergist shortage, telehealth is a legitimate and increasingly necessary access pathway. The rise of healthcare technology has made it easier than ever for patients in underserved areas to connect with board-certified specialists remotely.
Pediatric Allergy Treatment: Age-Specific Pathways and Early Intervention
Pediatric allergy care is not simply scaled-down adult care. The LEAP trial supports early peanut introduction in high-risk infants (4 to 11 months) as primary prevention, reflected in current AAP and AAAAI guidance.
Biologic eligibility varies by age: dupilumab for atopic dermatitis from 6 months, omalizumab and mepolizumab for asthma from 6 years, and benralizumab and tezepelumab from 12 years. Palforzia OIT serves ages 1 to 17, and the Viaskin Peanut Patch suits toddlers. SCIT generally begins at age 5 or older and can prevent progression from allergic rhinitis to asthma.
The “atopic march” describes the progression from infantile eczema to food allergy to allergic rhinitis to asthma. Early disease-modifying treatment may interrupt this trajectory. Parents should escalate to a pediatric allergist when symptoms persist or anaphylaxis risk is present.
Digital Health, AI, and Telemedicine: The New Infrastructure of Allergy Care
A 2026 peer-reviewed review in Frontiers in Allergy documents the expanding role of telemedicine platforms, AI-based decision support, and mobile health apps in allergy care and adherence. AI-powered tools integrate local pollen counts, weather data, and patient-reported symptoms to forecast flare-ups, shifting care from reactive to predictive (JACI: In Practice).
Telemedicine is particularly valuable for SLIT initiation and monitoring, follow-up consultations, and reaching rural populations. Mobile adherence apps improve immunotherapy completion rates, which have historically been plagued by dropout. However, telemedicine cannot replace in-person skin testing, SCIT administration, or anaphylaxis management. Patients can use digital tools to optimize care between specialist visits.
Health Equity in Allergy Care: Addressing Disparities and Access Barriers
Allergy disparities are significant and often unaddressed. Food allergy prevalence is rising faster among Black and Hispanic Americans, and Black children face higher rates of severe asthma and food allergy-related emergency room visits. Access barriers include insurance coverage gaps for immunotherapy and biologics, prior authorization burdens, and the geographic concentration of allergists in urban and suburban areas.
The 2025 ACAAI/AAAAI/AAOA joint guidance on documentation requirements directly responds to insurance barriers. The $371 billion food allergy cost includes substantial out-of-pocket spending that falls hardest on lower-income families.
Solutions include telehealth expansion, community health worker models, advocacy for immunotherapy insurance parity, and biologic patient assistance programs. Physicians should screen for social determinants of health and connect patients with AAFA, FARE, and manufacturer assistance programs. Addressing doctor-patient relationships with cultural competency and open communication is equally essential to closing these equity gaps.
Building an Allergy Treatment Plan: A Patient-Physician Collaboration Guide
- Accurate diagnosis first: Skin prick or specific IgE blood testing identifies triggers before escalation.
- Assess severity and impact: Validated tools (TNSS, RQLQ, ACQ) quantify disease burden.
- Start with guideline-concordant pharmacotherapy: Apply the 2026 ARIA-EAACI combination intranasal antihistamine plus corticosteroid recommendation for moderate-to-severe rhinitis.
- Consider immunotherapy early: Delaying AIT through years of failed pharmacotherapy is not advisable; it works best before extensive sensitization develops.
- Biomarker evaluation for biologics: If severe disease persists, obtain eosinophil count, FeNO, and IgE levels to guide selection.
- Monitor, adjust, and reassess: Seasonal changes, new sensitizations, and life stages (pregnancy and aging) require plan updates.
Shared decision-making matters. Patient preferences regarding injections versus sublingual therapy, clinic visit frequency, and cost are legitimate factors. Developing a comprehensive health plan in partnership with a specialist ensures that individual circumstances, comorbidities, and lifestyle factors are all accounted for. Red flags requiring urgent referral include any history of anaphylaxis, food-triggered anaphylaxis, severe uncontrolled asthma, or suspected primary immunodeficiency.
Conclusion: From Symptom Management to Disease Modification — The Standard of Care Has Evolved
The 2026 allergy landscape offers an unprecedented range of options: updated first-line guidelines, five FDA-approved biologics, established immunotherapy, and a robust pipeline of emerging therapies that enable true disease modification rather than symptom suppression. With climate change extending pollen seasons, a $371 billion economic burden, and rising prevalence across every demographic, the cost of undertreated allergies has never been higher.
The allergist/immunologist distinction matters, and knowing when to refer is a critical primary care competency. Digital health tools, AI-powered monitoring, and telemedicine are democratizing access and deserve recognition as legitimate components of modern care. For patients, the message is empowering: effective, personalized allergy treatment exists at every point on the severity spectrum. The key is finding the right specialist and the right rung on the treatment ladder.
Take the Next Step: Connect With an Allergy Specialist Today
Patients managing symptoms with OTC medications alone should schedule a consultation with a board-certified allergist or immunologist to explore whether immunotherapy or biologic therapy may be appropriate. Top Doctor Magazine’s physician directory and nomination platform can help patients find featured allergy and immunology specialists in their area.
For condition-specific information and specialist locators, patients and providers can consult authoritative resources from AAFA (aafa.org), FARE (foodallergy.org), AAAAI (aaaai.org), and ACAAI (acaai.org). Allergists and immunologists are encouraged to nominate themselves or colleagues for Top Doctor Magazine’s awards program, which recognizes specialists making a meaningful difference in patient care.
